arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

IGC Pharma, Inc.

IGC
$0.26 ▲ +0.01 (+2.94%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

IGC Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $25.5M
Dividend Yield
Revenue Growth -3.4%
Op. Margin None
ROIC -40.2%
FCF / Share $-0.01
Trailing P/E
Price / Book 4.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$317.00K
↓ -3.4%
Net Income Profit after all expenses
$-2.40M
↓ -50.2%
Operating Margin Operating profit as % of sales
-427.2%
↓ -1411.0%
FCF / Share Free cash flow per share
$-0.01
↑ +26.8%
Long-Term Debt Long-term obligations
$134.00K
↑ +1.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
0
Returns
7
Financial Health
47
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 65 quarters